Insmed shares jumped 8.1% to a nearly 25-year high after the FDA approved Brinsupri, the first therapy for non-cystic fibrosis bronchiectasis. The once-daily oral drug cut flare-ups by over 19% in trials. Analysts see a $5 billion-6 billion global market, with Wells Fargo, RBC, and BofA reiterating bullish views. Retail sentiment turned "extremely bullish".